An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is increasing in prevalence. … Read the full story from the UCSD Newsroom

Catriona H. M. Jamieson, MD, PhDPrincipal investigator of the study is Catriona H. M. Jamieson, MD, PhD, associate professor of medicine in the Division of Hematology-Oncology and director of stem cell research at the UC San Diego Moores Cancer Center.

Dr. Jamieson is on the steering committee for the Moores Cancer Center’s My Answer to Cancer initiative for personalized cancer therapy. She is a member of the faculty in the UCSD Biomedical Sciences Graduate Program.

Department of Medicine faculty coauthor Sheldon R. Morris, MD, MPH, an investigator at the UCSD Antiviral Research Center,is health sciences assistant clinical professor in the Division of Infectious Diseases.

Citation for the report in PNAS: Jiang Q, Crews LA, Barrett CL, Chun H-J, Court AC, Isquith JM, Zipeto MA, Goff DJ, Minden M, Sadarangani A, Rusert JM, Dao K-HT, Morris SR, Goldstein LSB, Marra MA, Kelly A. Frazer KA, Jamieson C.H.M. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. PNAS 2012; published ahead of print December 28, 2012, doi:10.1073/pnas.1213021110

Read the study report (free full text)

More about Dr. Jamieson and her work:

%d bloggers like this: